SCHEMBL477409

SCHEMBL477409

Cc1cccc(C(O)c2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 1/20 0.55
EPHX1 P07099 1/20 0.47
MLKL Q8NB16 1/20 0.47
ACHE P22303 3/20 0.46
TAAR1 Q96RJ0 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
OPRM1 P35372 1/20 0.43
OPRD1 P41143 1/20 0.43
OPRK1 P41145 1/20 0.43
OPRL1 P41146 1/20 0.43
HSD17B2 P37059 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
ALOX12 P18054 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
TACR1 P25103 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3859898 1.00 ACP3 (0.55) ACP3EPHX1MLKLACHETAAR1
SCHEMBL30502803 1.00 ACP3 (0.55) ACP3EPHX1MLKLACHETAAR1
SCHEMBL822105 0.93 ACHE (0.52) ACP3EPHX1MLKLACHETAAR1
SCHEMBL822299 0.89 ACP3 (0.44) ACP3EPHX1MLKLACHELMNA
SCHEMBL12792239 0.87 ACHE (0.52) ACP3EPHX1MLKLACHETAAR1
SCHEMBL12415923 0.86 TAAR1 (0.46) ACP3EPHX1MLKLTAAR1OPRM1
SCHEMBL11409330 0.86 ACHE (0.48) ACP3EPHX1MLKLACHE
SCHEMBL13027665 0.84 TACR1 (0.46) ACP3MLKLSMN1; SMN2SLC6A2SLC6A4
SCHEMBL23428902 0.84 CYP3A4 (0.42) ACP3ACHESMN1; SMN2OPRM1OPRK1
SCHEMBL8736883 0.84 CYP19A1 (0.46) ACP3ACHESMN1; SMN2SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11171293-B2 Organic electroluminescent element, material for organic electroluminescent element, light emitting device, display device and lighting device each using said element, and compound used for said element UDC IRELAND LIMITED (IE) 2021-11-09 US disclosed
EP-3828173-A1 SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BioCryst Pharmaceuticals, Inc. (US) 2021-06-02 EP disclosed
WO-2020155595-A1 AEROBIC OXIDATION SYSTEM CONTAINING SULFINIC ACID, SULFONIC ACID OR DERIVATIVES THEREOF AND PHOTOCATALYTIC OXIDATION METHOD THEREFOR 清华大学 2020-08-06 WO disclosed
CN-109053754-B Synthetic method for constructing polysubstituted chroman compound based on biomass source 2, 5-dimethylfuran dearomatization cycloaddition strategy 青岛农业大学 2020-04-07 CN disclosed
US-10025187-B2 Photosensitization chemical-amplification type resist material, method for forming pattern using same, semiconductor device, mask for lithography, and template for nanoimprinting TOKYO ELECTRON LIMITED (JP) 2018-07-17 US disclosed
US-10025187-B2 Photosensitization chemical-amplification type resist material, method for forming pattern using same, semiconductor device, mask for lithography, and template for nanoimprinting TOKYO ELECTRON LIMITED (JP) 2018-07-17 US disclosed
US-10018911-B2 Chemically amplified resist material and resist pattern-forming method JSR CORPORATION (JP) 2018-07-10 US disclosed
US-10018911-B2 Chemically amplified resist material and resist pattern-forming method JSR CORPORATION (JP) 2018-07-10 US disclosed
US-9971247-B2 Pattern-forming method OSAKA UNIVERSITY (JP) 2018-05-15 US disclosed
US-9971247-B2 Pattern-forming method OSAKA UNIVERSITY (JP) 2018-05-15 US disclosed
US-20080045757-A1 Chiral Tertiary Aminoalkylnaphthols THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 2008-02-21 US disclosed
US-7304057-B2 Substituted 6-membered N-heterocyclic compounds and method for their use as neurological regulator Institute of Pharmacology and Toxicology Accademy of Military Medical Sciences P.L.A. China (CN) 2007-12-04 US disclosed
EP-0983222-B1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 2007-11-28 EP disclosed
US-7291753-B2 Transfer hydrogenation processes and catalysts ABDUR-RASHID KAMALUDDIN 2007-11-06 US disclosed
US-20070213361-A1 Preventive and/or therapeutic agent for neutrophilic inflammatory diseases KYOWA KIRIN CO., LTD. (JP) 2007-09-13 US disclosed
US-20070213361-A1 Preventive and/or therapeutic agent for neutrophilic inflammatory diseases KYOWA KIRIN CO., LTD. (JP) 2007-09-13 US disclosed
CN-1930116-A Chiral tertiary aminoalkylnaphthols UNIV HONG KONG POLYTECHNIC (HK) 2007-03-14 CN disclosed
US-20050130958-A1 Substituted 6−membered n−heterocyclic compounds and their uses as neurological regulator INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2005-06-16 US disclosed
CN-1173960-C Substituted hexa azacylo compounds and their use as neuroregulator �й������ž�����ҽѧ��ѧԺ����ҩ 2004-11-03 CN disclosed
CN-1422852-A Substituted hexa azacylo compounds and their use as neuroregulator TOXICANT AND MEDICINE INST MIL (CN) 2003-06-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10025187-B2 Photosensitization chemical-amplification type resist material, method for forming pattern using same, semiconductor device, mask for lithography, and template for nanoimprinting ASIC1, ASIC3, CLTA ACP3 1387/4885EPHX1 2407/4885MLKL 778/4885
US-20080045757-A1 Chiral Tertiary Aminoalkylnaphthols ALDH7A1, ADH5, ALDH1A1 ACP3 2390/4885EPHX1 74/4885MLKL 4852/4885
US-11171293-B2 Organic electroluminescent element, material for organic electroluminescent element, light emitting device, display device and lighting device each using said element, and compound used for said element L1CAM, OR10J3, INTS9 ACP3 4831/4885EPHX1 188/4885MLKL 2886/4885
US-10018911-B2 Chemically amplified resist material and resist pattern-forming method SLC11A2, XRCC5, RAD54L ACP3 1408/4885EPHX1 3210/4885MLKL 1306/4885
US-20070213361-A1 Preventive and/or therapeutic agent for neutrophilic inflammatory diseases MPO, MSR1, NR4A3 ACP3 1595/4885EPHX1 827/4885MLKL 3203/4885
US-20050130958-A1 Substituted 6−membered n−heterocyclic compounds and their uses as neurological regulator BDNF, NGF, NTRK2 ACP3 1126/4885EPHX1 2936/4885MLKL 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.